Navigation Links
Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
Date:5/13/2010

-person">Dennis Turpin, Senior Vice President and Chief Financial Officer of Aeterna Zentaris added, "With more than $40 million in cash, including proceeds from our recent $15 million registered direct offering and no debt, combined with our expected significantly reduced burn rate, we are in a solid financial position to execute our focused drug development and business strategy."

CONSOLIDATED RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2010

Revenues were $6.4 million for the three-month period ended March 31, 2010, compared to $6.1 million for the same period in 2009. The increase is mainly due to a comparative increase in sales of Cetrotide(R) to certain customers in the first quarter of 2010. This increase was partly offset by lower amortization of upfront license fee payments in 2010 related to our agreement with sanofi-aventis U.S. LLC ("sanofi-aventis"), which was entered into in March 2009, in connection with our now discontinued development program involving cetrorelix for the treatment of Benign Prostatic Hyperplasia ("BPH"), and subsequently terminated.

Research and development ("R&D") costs, net of tax credits and grants, were $5.7 million for the three-month period ended March 31, 2010, compared to $11.4 million for the same period in 2009. The comparative decrease in net R&D costs is almost entirely attributable to the winding down and termination of development activities related to cetrorelix in BPH, despite the presence in the first quarter of 2010 of residual expenditures associated with certain remaining contractual obligations.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
2. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
3. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
5. AEterna Zentaris Announces Appointment of New Board Member
6. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
8. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
9. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
10. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
11. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... DALLAS , May 22, 2015 Baylor ... and the Translational Genomics Research Institute (TGen) in ... that will focus on accelerating early detection and treatments for ... science of both institutions will lead to new clinical trials ... therapies – bridging the gap from bench to bedside across ...
(Date:5/21/2015)... PLAINSBORO, N.J. (PRWEB) May 21, 2015 ... initial circulation audit and been admitted to BPA ... result, BPA Worldwide will track audience data for ... geographic coverage. , “By becoming a member ... steadfast dedication to providing our clients with the ...
(Date:5/21/2015)... San Francisco, CA (PRWEB) May 21, 2015 ... microbiome sequencing, has announced a partnership with PicnicHealth, ... records for patients. Participants diagnosed with Inflammatory Bowel ... as well as a complementary uBiome research kit. ... Summer 2014. , For more ...
(Date:5/21/2015)... Worms, Germany (PRWEB) May 21, 2015 ... announces that its manufacturing facility in Worms, Germany ... EXCiPACT™, an independent subsidiary of the International Pharmaceutical ... three Grace facilities that produce its SYLOID® FP ... now received GMP certification, following the Curtis Bay, ...
Breaking Biology Technology:Precision Medicine Collaboration to Increase Options for Cancer Patients 2Precision Medicine Collaboration to Increase Options for Cancer Patients 3Precision Medicine Collaboration to Increase Options for Cancer Patients 4Specialty Pharmacy Times Joins BPA Worldwide 2uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2
... Everyone would like MDs to have the best education ... in the April 4 issue of the journal Academic ... how to incorporate this understanding into real world education, particularly ... tried and true teaching strategies. Now, knowing what is happening ...
... March 30, 2011 Spherix Incorporated (Nasdaq: ... in diabetes, metabolic syndrome and atherosclerosis and provider of ... and pharmaceutical companies – today reported financial results for ... Recent and Upcoming Highlights Pharmaceutical ...
... 30, 2011 EntreMed, Inc. (Nasdaq: ENMD ... treatment of cancer, today reported results for the three ... (Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO) For fiscal year ... for fiscal 2009.  For the year ended December 31, ...
Cached Biology Technology:Brain scientists offer medical educators tips on the neurobiology of learning 2Brain scientists offer medical educators tips on the neurobiology of learning 3Brain scientists offer medical educators tips on the neurobiology of learning 4Brain scientists offer medical educators tips on the neurobiology of learning 5Spherix Announces 2010 Financial Results 2Spherix Announces 2010 Financial Results 3Spherix Announces 2010 Financial Results 4Spherix Announces 2010 Financial Results 5Spherix Announces 2010 Financial Results 6Spherix Announces 2010 Financial Results 7EntreMed Reports Fourth Quarter and Year-End 2010 Financial Results 2EntreMed Reports Fourth Quarter and Year-End 2010 Financial Results 3EntreMed Reports Fourth Quarter and Year-End 2010 Financial Results 4
(Date:4/27/2015)... Apr. 27, 2015 Profile Solutions, Inc. (OTC: ... security systems is pleased to announce that Dr ... consultant and member of its scientific advisory board. ... as a thought leader in technology-enhanced learning models. He ... and has published studies and books focused on online ...
(Date:4/14/2015)...  HYPR Corp. today announced it has joined ... tm , an industry consortium transforming online authentication ... technology and collaborate to deliver open specifications for ... and private, and easier to use. ... sensitive user information and eliminates the dependency on ...
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... 23, 2015, after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2
... the quality of local water increases the resistance of coral ... in June in Marine Ecology Progress Series . Florida ... his student Dan Wagner led the study, which provides concrete ... for reefs in a rapidly changing world. Van ...
... new computer data compression technique called Genomic SQueeZ (G-SQZ), developed ... researchers and others to store, analyze and share massive volumes ... Created specifically for genomic sequencing data, the encoding method underlying ... published today in the journal Bioinformatics . Tests ...
... Trek fans will remember "tractor beams," lasers that allowed the ... is now turning this science fiction into science fact -- ... Tel Aviv University, Holographic Optical Tweezers (HOTs) use holographic technology ... as beads of glass or polymer, that are too small ...
Cached Biology News:New TGen technology reduces storage needs and costs for genomic data 2New TGen technology reduces storage needs and costs for genomic data 3A pinch of light 2
Values of steady state parameters for enzyme activities are determined....
... analysis can be used for the identification of ... monitor renal and other diseases. Due to the ... large amounts, it provides an attractive alternative to ... biomarkers. The ProteoSpin Urine Protein Concentration Micro ...
... The ProteinChip Antibody ... assay development and optimization ... evaluate antibody-antigen interactions. This ... and differentiation of multiple ...
... The Bioactive peptides are molecules of peptidic ... behaviour or activity which can be developed ... chemical and agro-food applications. In this way ... with superior properties for therapeutic applications. Primm ...
Biology Products: